A bill to direct the Food and Drug Administration to prevent the importation of counterfeit, unapproved, misbranded, or adulterated drugs from the People's Republic of China or other foreign countries, to establish enhanced safeguards for imported drug products, and for other purposes.

On July 21, 2026, Sen. Ted Budd (R-NC) introduced S5043 in the 119th Congress. The bill was read twice and referred to the Committee on Health, Education, Labor, and Pensions. It has zero cosponsors and only two actions: introduction and referral. The bill's objective is to direct the FDA to prevent importation of counterfeit, unapproved, misbranded, or adulterated drugs from China or other foreign countries, and to establish enhanced safeguards for imported drug products. As an early-stage bill with no companion legislation, no committee hearings, and no funding authorization, its probability of near-term passage is low. The legislative path requires committee markup, floor debate, and House passage before any potential enactment. No specific funding amounts are authorized or appropriated. The bill does not directly name any company or product line, and its impact on specific healthcare companies is speculative at this stage. The primary effect, if enacted, would be to increase regulatory compliance costs for importers of pharmaceutical ingredients, potentially benefiting domestic manufacturers of generic drugs and active pharmaceutical ingredients (APIs). However, without further legislative momentum, no actionable market signal exists.